Seasonal Allergic RhinitisPhase 2NCT07436234
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis
A Phase 2 study testing AK139 in people with Seasonal Allergic Rhinitis, run by Akeso at 1 site in China.
Trial summary
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Seasonal Allergic Rhinitis
- What is being tested?
- AK139
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 111 participants
- Where
- 1 siteChina
- Study dates
- 2 Mar 2026to 13 May 2027
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female aged 18-65.
- Able to understand the study and voluntarily sign the ICF;
- Diagnosed SAR according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition), with or without allergic conjunctivitis, and have SAR history at least two years;
- Have immunoglobulin E (Ig E)-mediated hypersensitivity to at least one pollen allergen in the current environment;
- The SAR symptoms of participants remained inadequately control ledafter nasal spray corticosteroids and/or other SAR medications treatment throughout the previous same pollen season;
- Adequate pollen exposure during the pollen season.
Show all 9Show fewer
- The SAR symptoms scores of the participants meet the requirements of the protocol at screening and baseline.
- During the screening/run-in period, participants must complete at least 80% of the assessments in the diary card;
- The participants agree to use highly effective contraception methods from the moment of signing of the ICF to 3 months after the last dose of the investigational product.
Who cannot join
- Type of rhinitis other than allergic rhinitis within 2 weeks before screening;
- Allergic to any component of the investigational drug or intolerant to basis treatment..
- Concomitant or associated nasal diseases/conditions that, as determined by investigators, may affect the severity of the disease and the evaluation of therapeutic effects.
- Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to.
- Other reasons the investigators believes that the participants is not suitable to enrolled in this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe SAR
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR
Read the detailed description
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR. Participants will be randomized to receive AK139 regimen or placebo subcutaneous injection and followed up to week 12
- Conditions
- Seasonal Allergic Rhinitis
- Being tested
- AK139, Placebo
- Medical subject headings
- Rhinitis, Allergic, Seasonal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AK139Drug
AK139 regimen 1- subcutaneous injection.
AK139Drug
AK139 regimen 2- subcutaneous injection
PlaceboDrug
Placebo-subcutaneous injection
| Study group | Role | What they receive |
|---|---|---|
| AK139 regimen 1 | Experimental | Not described Receives: Drug: AK139 |
| AK139 regimen 2 | Experimental | Not described Receives: Drug: AK139 |
| Placebo | Experimental | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 2 weeks of treatment
Measured: Up to week 2
Incidence of adverse events (AEs)
Measured: Up to week 12
Secondary outcomes (4)
Mean change from baseline in daily rTNSS over 2 and 4 weeks of treatment
Measured: Up to week 4
Mean change from baseline in the daily AM and PM reflective total nasal symptom score (AM and PM rTNSS) over 2 and 4 weeks of treatment
Measured: Up to week 4
Serum AK139 concentration
Measured: Up to week 12
Number of participants with detectable anti-drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.
Measured: Up to week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start2 Mar 2026 (estimated)
- Primary completion30 Sep 2026 (estimated)
- Study completion13 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Seasonal Allergic RhinitisStudies of the same condition, open and under way.
- More trials run by AkesoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 111 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Akeso
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07436234
- Sponsor's protocol ID
- AK139-203
- Status last verified
- Feb 2026
- First submitted
- 3 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No